Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Whether you are working with semaglutide or tirzepatide , brand-name or compounded formulations , the protocols and calculators available through SeekPeptides membership eliminate the guesswork that makes GLP-1 therapy unnecessarily complicated
:
Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
2 Choose your treatment option A U.S
GLP-1 Coverage
Not one pathway
US$ 29.35
US$ 29.51
US$ 28.30
